Long term tolerability and clinical outcomes associated with tocilizumab in the treatment of refractory antibody mediated rejection (AMR) in pediatric renal transplant recipients.
Meghan H PearlPatricia L WengLucia ChenAditi DokrasHelen PizzoJonathan GarrisonCarrie L ButlerJennifer ZhangElaine F ReedIrene K KimJua ChoiMark HaasXiaohai ZhangAshley VoEileen Tsai ChambersRobert EttengerStanley JordanDechu PuliyandaPublished in: Clinical transplantation (2022)
Tocilizumab in pediatric patients with refractory AMR was well tolerated and appeared to stabilize renal function. The utility of tocilizumab in the treatment of AMR in this population should be further explored.